Government Cracks Down on Fake DNA-Based Medicine
By Eric Hal Schwartz,
In The Capital
| 05. 13. 2014
Any medical advance always brings along con men hoping to exploit the news with useless or even dangerous "medicine" of their own that they can lie about to sell to people who don't yet know how to spot fakes. Personalized medicine, treatment that uses genetic information to improve people's health, has now reached the point where companies eager to cheat people excited by its promise are sprouting up. The Federal Trade Commission has taken the first steps to quashing these 21st century snake-oil salesmen in a settlement finalized Tuesday with two "personalized nutritional supplement" companies.
Genomics and personalized medicine has the potential to help countless people by diagnosing cancer earlier, treating genetic diseases and even restoring organs and tissue. It's still early days for the field and the FDA and FTC are watching closely as techniques and products are developed. GeneLink, Inc. and its former subsidiary, foruTMInternational Corp., were also watching, and created an entire scam around the idea of personalized medicine. Customers would send them a cheek swab and the companies claimed they would analyze the DNA and...
Related Articles
By Matt Novak, Gizmodo | 07.23.2025
Robert F. Kennedy Jr., the Secretary of Health and Human Services, has made a big push to get agencies like the Food and Drug Administration to use generative artificial intelligence tools. In fact, Kennedy recently told Tucker Carlson that AI...
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...